CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results
December 13, 2023 16:05 ET
|
Cargo Therapeutics, Inc.
SAN MATEO, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell...
CARGO Therapeutics Announces Scientific Advisory Board
December 06, 2023 08:05 ET
|
Cargo Therapeutics, Inc.
SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell...
CARGO Therapeutics Announces Appointment of Ginna Laport, MD, as Chief Medical Officer
October 17, 2023 09:05 ET
|
CARGO Therapeutics, Inc.
— Accomplished clinical leader with significant expertise in hematology/oncology drug development and a track record of advancing multiple modalities of cancer therapeutics — SAN MATEO, Calif., Oct. ...
CARGO Therapeutics Announces Appointment of Michael Ports, PhD, as Chief Scientific Officer
September 12, 2023 09:05 ET
|
CARGO Therapeutics, Inc.
– Scientific leader with multi-company cell therapy drug development experience spanning early discovery initiatives through late-stage development – SAN MATEO, Calif., Sept. 12, 2023 (GLOBE...
CARGO Therapeutics Appoints Biotech Life Sciences Leaders to Board of Directors
August 24, 2023 09:05 ET
|
CARGO Therapeutics, Inc.
– Board of Director appointments follow the Company’s recent launch and $200 million Series A financing in March 2023 – – Appointments include industry veterans John Orwin as Chairman, David Lubner...
Precision BioSciences to Report Fiscal Year and Fourth Quarter 2019 Financial Results and Present at Upcoming Investor Conferences
February 21, 2020 07:00 ET
|
Precision Biosciences
DURHAM, N.C., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary...